| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-3-0348-0955-9_4 |
| P698 | PubMed publication ID | 26608200 |
| P2093 | author name string | Ondrej Slaby | |
| Petra Vychytilova-Faltejskova | |||
| P2860 | cites work | Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors | Q21134548 |
| Epidemiology of esophageal cancer | Q24625927 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Circulating microRNAs: macro-utility as markers of prostate cancer? | Q27000024 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 | ||
| Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development | Q28284070 | ||
| Malignant tumors of the female reproductive system | Q28388678 | ||
| Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers | Q28391728 | ||
| Circulating MiR-125b as a marker predicting chemoresistance in breast cancer | Q28482362 | ||
| Serum microRNA biomarkers for detection of non-small cell lung cancer | Q28731643 | ||
| Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels | Q30502172 | ||
| MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. | Q30541314 | ||
| Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue | Q33331288 | ||
| Circulating microRNAs in breast cancer and healthy subjects | Q33447949 | ||
| A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer | Q33555195 | ||
| Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer | Q36594062 | ||
| Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma | Q36671959 | ||
| Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer | Q36820516 | ||
| Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort | Q36997902 | ||
| Circulating microRNAs predict biochemical recurrence in prostate cancer patients | Q37081843 | ||
| Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer | Q37093290 | ||
| Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma | Q37196131 | ||
| Serum circulating microRNA profiling for identification of potential breast cancer biomarkers | Q37260646 | ||
| Higher expression of circulating miR-182 as a novel biomarker for breast cancer | Q37326193 | ||
| The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies | Q37349623 | ||
| Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients | Q37394399 | ||
| Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. | Q37438786 | ||
| Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs | Q37439272 | ||
| High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer | Q37451898 | ||
| Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery | Q37479781 | ||
| A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma | Q37499747 | ||
| Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. | Q37548836 | ||
| Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma | Q37548853 | ||
| Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes | Q37594361 | ||
| Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer | Q37594418 | ||
| Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer | Q37605740 | ||
| A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool | Q37641229 | ||
| Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. | Q37659419 | ||
| Genetics of adult glioma | Q38067239 | ||
| The role of microRNAs in tumors | Q38123756 | ||
| MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas | Q38178272 | ||
| miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients | Q38476677 | ||
| Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer | Q38675709 | ||
| Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression | Q38970049 | ||
| Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer | Q38987433 | ||
| Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer | Q39147491 | ||
| Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma | Q39167703 | ||
| Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. | Q39217323 | ||
| Circulatory miR-628-5p is downregulated in prostate cancer patients | Q39260664 | ||
| Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy | Q33572407 | ||
| Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer | Q33613644 | ||
| Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion | Q33619253 | ||
| Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer | Q33654179 | ||
| Circulating MicroRNAs in gynecological malignancies: from detection to prediction | Q33718986 | ||
| Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis | Q33735297 | ||
| A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer | Q33742015 | ||
| Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum | Q33824699 | ||
| microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer | Q34008192 | ||
| Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study | Q34020155 | ||
| Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma | Q34028475 | ||
| MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels | Q34045027 | ||
| Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection | Q34103110 | ||
| Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. | Q34123686 | ||
| Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression | Q34140780 | ||
| Expression Profile of MicroRNAs in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma | Q34143366 | ||
| Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma | Q34151439 | ||
| Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 | ||
| Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer | Q34202973 | ||
| A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus | Q34216030 | ||
| Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer | Q34240615 | ||
| The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research | Q34252557 | ||
| Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. | Q34253117 | ||
| The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer | Q34273062 | ||
| Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas | Q34279430 | ||
| Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma | Q34354560 | ||
| Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma | Q34374389 | ||
| Cancer of the ovary | Q34375262 | ||
| Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma | Q34393036 | ||
| Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer | Q34399019 | ||
| Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer | Q34412367 | ||
| Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma | Q34441361 | ||
| Serum microRNA-155 as a potential biomarker to track disease in breast cancer | Q34447755 | ||
| Epidemiology and risk factors for kidney cancer | Q34449963 | ||
| Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. | Q53280056 | ||
| Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. | Q53416418 | ||
| Preoperative Prediction of Lymph Node Status by Circulating Mir-18b and Mir-20a During Chemoradiotherapy in Patients with Rectal Cancer. | Q53499619 | ||
| Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma. | Q53531177 | ||
| Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. | Q53556224 | ||
| Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma. | Q53566415 | ||
| Plasma miR-221/222 Family as Novel Descriptive and Prognostic Biomarkers for Glioma. | Q53624071 | ||
| A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. | Q53651538 | ||
| Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. | Q53673720 | ||
| Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study. | Q53807179 | ||
| Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. | Q54196115 | ||
| Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. | Q54224712 | ||
| Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. | Q54225125 | ||
| Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. | Q54229169 | ||
| Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. | Q54252991 | ||
| Decreased levels of circulating and tissue miR-107 in human esophageal cancer. | Q54261697 | ||
| Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? | Q35828512 | ||
| Adjuvant and neoadjuvant treatment in pancreatic cancer | Q35886631 | ||
| Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. | Q35922727 | ||
| De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer | Q35927834 | ||
| Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer | Q36214432 | ||
| Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma | Q36214725 | ||
| Circulating cell-free miRNAs as biomarker for triple-negative breast cancer | Q36285931 | ||
| Serum microRNAs as biomarkers for recurrence in melanoma. | Q36341127 | ||
| Lymphangiogenesis and biological behavior in pancreatic carcinoma and other pancreatic tumors | Q36383098 | ||
| Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer | Q36388236 | ||
| Differential expression of miRNAs in the serum of patients with high-risk oral lesions | Q36530712 | ||
| Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 | ||
| Circulating microRNAs as novel minimally invasive biomarkers for breast cancer | Q39281588 | ||
| Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients | Q39379218 | ||
| The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma | Q39420546 | ||
| Determination of plasma microRNA for early detection of gastric cancer. | Q39508309 | ||
| MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease | Q39950193 | ||
| Circulating microRNAs in plasma of patients with gastric cancers | Q39986294 | ||
| Profiling of circulating microRNAs for prostate cancer biomarker discovery. | Q40264691 | ||
| Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment | Q41134824 | ||
| Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma | Q41530973 | ||
| Expression of serum let-7c, let-7i, and let-7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease | Q41570877 | ||
| MicroRNA Expression can be a Promising Strategy for the Detection of Barrett's Esophagus: A Pilot Study | Q41696429 | ||
| Expression and significance of circulating microRNA-31 in lung cancer patients | Q41987857 | ||
| Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer | Q42112822 | ||
| An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions | Q42140417 | ||
| Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma | Q42199617 | ||
| Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. | Q42233721 | ||
| Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. | Q42267974 | ||
| Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival | Q43137654 | ||
| Identification of circulating microRNA signatures for breast cancer detection | Q43511958 | ||
| Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer | Q43554998 | ||
| A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. | Q43686660 | ||
| Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer | Q43873674 | ||
| Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer | Q44030040 | ||
| Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients | Q44132305 | ||
| Aberrant expression of miR-196a in gastric cancers and correlation with recurrence | Q44158395 | ||
| A panel of five circulating microRNAs as potential biomarkers for prostate cancer | Q44430269 | ||
| Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer | Q44499697 | ||
| Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma | Q44500035 | ||
| Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). | Q44502866 | ||
| Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). | Q45181282 | ||
| Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. | Q45202446 | ||
| Bladder cancer: epidemiology, staging and grading, and diagnosis. | Q45247416 | ||
| Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma | Q45361542 | ||
| Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer | Q45426468 | ||
| Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma | Q45836927 | ||
| Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer | Q45892221 | ||
| Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. | Q46396991 | ||
| Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer | Q46422776 | ||
| Sensitive detection of melanoma metastasis using circulating microRNA expression profiles | Q46604823 | ||
| The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers | Q46925242 | ||
| Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening | Q48466686 | ||
| Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. | Q50498335 | ||
| Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. | Q50924410 | ||
| Role of microRNAs -29b-2, -155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. | Q51060301 | ||
| MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. | Q51061144 | ||
| Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. | Q51149290 | ||
| Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. | Q51768821 | ||
| MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. | Q52958254 | ||
| Serum microRNAs in clear cell carcinoma of the ovary. | Q53161410 | ||
| Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. | Q53173121 | ||
| Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients | Q34496664 | ||
| Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer | Q34526484 | ||
| Circulating microRNAs as specific biomarkers for breast cancer detection. | Q34542335 | ||
| miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer | Q34544501 | ||
| Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer | Q34613472 | ||
| Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis | Q34693160 | ||
| Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients | Q34735084 | ||
| Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer | Q34768088 | ||
| Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer | Q34775829 | ||
| Whole-miRNome profiling identifies prognostic serum miRNAs in esophageal adenocarcinoma: the influence of Helicobacter pylori infection status | Q34917987 | ||
| Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma | Q35018941 | ||
| Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer | Q35023641 | ||
| Plasma microRNA panel for minimally invasive detection of breast cancer | Q35032320 | ||
| Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma | Q35038304 | ||
| Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer | Q35040690 | ||
| Reduced expression levels of let-7c in human breast cancer patients | Q35042277 | ||
| Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer | Q35093548 | ||
| Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. | Q35098328 | ||
| Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma | Q35108381 | ||
| Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer | Q35110766 | ||
| MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers | Q35113043 | ||
| Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma | Q35126364 | ||
| Circulating exosomal microRNAs as biomarkers of colon cancer. | Q35140085 | ||
| Identification of a circulating microRNA signature for colorectal cancer detection | Q35141718 | ||
| Serum microRNA-205 as a novel biomarker for cervical cancer patients | Q35189400 | ||
| Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers | Q35218751 | ||
| Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma | Q35275041 | ||
| Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. | Q35518887 | ||
| Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression | Q35535686 | ||
| Analysis of Glioblastoma Patients' Plasma Revealed the Presence of MicroRNAs with a Prognostic Impact on Survival and Those of Viral Origin | Q35581594 | ||
| Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer | Q35623347 | ||
| A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. | Q35644072 | ||
| Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer | Q35675384 | ||
| miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy | Q35681504 | ||
| A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients | Q35740150 | ||
| Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. | Q54264657 | ||
| Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. | Q54274193 | ||
| Circulating microRNAs in plasma as early detection markers for breast cancer. | Q54294896 | ||
| Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. | Q54322917 | ||
| Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. | Q54329843 | ||
| The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. | Q54365633 | ||
| The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. | Q54390629 | ||
| miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. | Q54392168 | ||
| A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis | Q54399995 | ||
| Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. | Q54456800 | ||
| The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform | Q54997659 | ||
| Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. | Q55460538 | ||
| Is Early Detection of Cancer with Circulating Biomarkers Feasible? | Q57940509 | ||
| miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer | Q63253996 | ||
| Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma | Q63432579 | ||
| The rational clinical examination. Does this patient have a mole or a melanoma? | Q74298332 | ||
| Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer | Q83121081 | ||
| Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis | Q83181319 | ||
| Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer | Q83195745 | ||
| Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer | Q83316012 | ||
| High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer | Q83943983 | ||
| Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma | Q84028708 | ||
| Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis | Q84071421 | ||
| Circulating miRNAs are correlated with tumor progression in prostate cancer | Q84232903 | ||
| Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer | Q84484734 | ||
| Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients | Q84561982 | ||
| Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis | Q84582500 | ||
| Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer | Q84828208 | ||
| Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? | Q85784261 | ||
| Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening | Q86267440 | ||
| Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer | Q86560697 | ||
| Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor | Q86619953 | ||
| MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer | Q86892940 | ||
| A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study | Q87173491 | ||
| Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer | Q87269128 | ||
| Serum microRNA-92 expression in patients with ovarian epithelial carcinoma | Q87287824 | ||
| Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer | Q87319145 | ||
| Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus | Q87341840 | ||
| Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer | Q87592924 | ||
| Increased micro-RNA 17, 21, and 192 gene expressions improve early diagnosis in non-small cell lung cancer | Q87636779 | ||
| A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer | Q87964695 | ||
| Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma | Q87985149 | ||
| Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | Q88092055 | ||
| Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer | Q88112156 | ||
| Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer | Q88147904 | ||
| Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer | Q95383732 | ||
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 75-122 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | EXS | Q27709924 |
| P1476 | title | Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors | |
| P478 | volume | 106 |
Search more.